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Abstract
Up to 70% of U.S. businesses in the biotech industry received Food and Drug
Administration (FDA) noncompliance citations in 2015. The effective implementation of
quality management strategies may lead to improved quality compliance. The purpose of
this qualitative multiple case study was to explore the strategies that quality compliance
managers in biotech companies use to integrate and apply FDA product quality
compliance requirements into their products’ quality compliance metrics. Deming’s
strategic models for developing and implementing quality provided the conceptual
framework for the study. The study participants consisted of five biotech quality
compliance managers in the West region of the United States who had successfully
implemented strategies to integrate and apply FDA product quality compliance
requirements into their quality compliance metrics. Data were collected from
semistructured interviews and public documents. Data were analyzed according to Yin’s
5-step process of compiling, disassembling, interpreting, and making conclusions. Three
themes emerged from the data analysis: product quality outcomes, policies and
procedures, and collaborative partnerships. A key recommendation includes compliance
managers identifying collaborative quality compliance opportunities within and outside
their organizations. The implications for positive social changes include the availability
of needed drugs for society. Growth in the biotech industry may improve the overall
health and living conditions of the public.
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Section 1: Foundation of the Study
As the biotech industry becomes increasingly larger and faster paced, the Food
and Drug Administration’s (FDA’s) quality regulatory regime becomes even more
stringent (Huang et al., 2020). Improved regulatory quality compliance strategies have
become imperative for compliance managers in the biotech industry (Huang et al., 2020).
As Chen et al. (2019) noted, manufacturers must think about quality compliance from the
early product development phase and should also consider FDA quality compliance
requirements. The lack of quality compliance accounts for failing profit in the biotech
industry (Katamesh et al., 2019). Quality compliance managers should develop quality
compliance strategies to attain full FDA product quality compliance requirements as best
practices (Chen et al.,2019). My focus in this qualitative multiple case study was to
explore the strategies used by quality compliance managers in the biotech industry to
attain full FDA product quality compliance. Identifying the strategies used in the industry
to attain FDA product quality compliance may result in improved compliance in the
industry, may improve industry profitability, and may reduce the number of
noncompliance citations received in the industry.
Background of the Problem
Biotech firms received quadrupled FDA noncompliance citations in 2015
(Katamesh et al., 2019). Katamesh et al. (2019) further noted that noncompliance with
FDA product quality regulations had continued to negatively impact the industry’s
profitability. According to Wang et al. (2016), noncompliance with the FDA’s product
quality regulations in the biotechnology industry impacts the industry’s profitability and
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has a negative impact on future research outcomes. The FDA reported a 64% increase in
the amount of current Good Manufacturing Practice (cGMP) noncompliance from 2007
to 2012 (Wang et al., 2016). Despite the development of new products in the biotech
industry, financial growth rate was low due to an increase in associated product quality
compliance fines and citation costs (Katamesh et al., 2019). My focus in this qualitative
multiple case study was to explore the strategies used by biotech companies to integrate
FDA product quality requirements into their product quality metrics.
Problem Statement
The slow growth rate and failing profit of U.S. biotechnology industry is tied to
the FDA’s product quality compliance and enforcement regulations (Fox et al., 2017).
Noncompliance with the FDA’s product quality regulation in the biotechnology industry
impacts the industry’s profitability and has a negative impact on future research outcomes
(Katamesh et al., 2019). The FDA reported a 64% increase in the amount of current
cGMP noncompliance from 2007 to 2012 (Wang et al., 2016). The general business
problem was the biotech industry is unable to incorporate FDA quality compliance
requirements into their operational business practices despite its impact on their
profitability. The specific business problem was some quality compliance managers in
the biotech industry do not have the strategies to integrate and apply FDA quality
compliance requirements into their products’ quality metrics.
Purpose Statement
The purpose of this qualitative multiple case study is to explore the strategies that
quality compliance managers in biotech companies use to integrate and apply FDA
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product quality compliance requirements into their products’ quality compliance metrics.
The target population consisted of five biotech quality compliance managers in the West
region of the United States who had successfully implemented strategies to integrate and
apply FDA product quality compliance requirements into their quality compliance
metrics. The findings of this study may contribute to social change by providing the U.S.
population with more rapid access to urgently needed drugs and treatment. The findings
from this study may also help to mitigate FDA citation compliance violation cost
incurred by the biopharmaceutical industry, which is typically passed down to the public
in the form of higher drug costs.
Nature of the Study
For this study, I considered three research methods: (a) quantitative, (b)
qualitative, and (c) mixed. After considering these research methods, I chose the
qualitative method. Qualitative methodology is appropriate for creating a deeper
understanding of a contemporary phenomenon within a real-world context (Bernard,
2013). According to Yin (2017), using the qualitative research method provides an
opportunity for a better understanding of the subject of study. As Ritchie et al., (2016)
opined, using the qualitative method provides the researcher with a naturalistic
interpretive approach to understanding the meaning of events and phenomena. In
contrast, the quantitative research method is used to test hypotheses about variables’
relationships (Jacob et al., 2015). The quantitative research method was unsuitable for
this study’s focus on identifying and exploring the strategies used by quality compliance
managers to integrate and apply FDA quality compliance requirements into their
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companies’ quality metrics. Quantitative methodology was rejected because I did not
need to examine variables’ relationships through testing a hypothesis to address my
study’s purpose. Researchers use mixed methods when combining qualitative and
quantitative methods in one study. I rejected the mixed-methods approach because I did
not need to combine quantitative and qualitative methods. I used a qualitative method
because employing a qualitative method would enable a detailed analysis of the different
strategies used by quality compliance managers in the biotech industry to integrate and
apply FDA quality compliance requirements into their products’ quality metrics.
I chose a multiple case study design for this study. A case study design was
suitable for this study because using a case study design would enable me to ask what,
how, and why questions. Researchers use multiple case study designs to understand the
similarities and differences between cases (Yin,2017). Baškarada (2016) argued that
researchers use the multiple case study design to generate evidence from multiple cases,
which makes the study more reliable. I selected a multiple case study for this study to
clarify findings and to ensure a wider discovery of evidence to answer the research
question. Yin (2017) argued that using case study designs enables the researcher to
answer what, how, and why questions more effectively than any other design. In the
current study, I wanted to identify and explore the strategies used by compliance
managers when formulating and integrating current FDA quality compliance
requirements into their products’ quality metrics. I considered other designs such as (a)
narrative, (b) ethnography, and (c) phenomenology.
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Researchers use the narrative design to explore research participants’ personal
stories. The current study focused on business strategies and not personal stories.
Therefore, the narrative design was unsuitable. Researchers use the ethnographic design
to study participants’ daily lives, community processes, and activities in a defined study
population (Small et al., 2014). Also, researchers use the ethnographic design to study
social interaction and culture of a group of people (Hoeber & Shaw, 2017). I did not
address any social interactions in this study; therefore, the ethnographic design was
unsuitable. Phenomenology researchers seek to understand the meanings of participants’
personal experiences with a phenomenon. I rejected the phenomenological design
because I did not focus on identifying and exploring the personal meanings of
participants’ experience of a phenomenon. Rather, I focused on identifying and exploring
business strategies. The multiple case study design was appropriate for this study because
employing a case study design allowed me to effectively explore the strategies used by
quality compliance managers to integrate and apply FDA quality compliance
requirements into their products’ quality compliance metrics.
Research Question
What are the strategies use by quality compliance managers in the biotech
industry to integrate and apply FDA quality compliance requirements into their products’
quality metrics?
Interview Questions
The following interview questions were used to answer the research question:
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1. What leadership strategies do you use to embed a culture of quality and
compliance within your company?
2. How does your management team formulate and adopt product quality
compliance techniques?
3. How does your organization integrate quality compliance strategies into your
internal and/or external quality compliance metric systems?
4. What total quality management processes and tool does your organization use
to implement your quality management strategies?
5. How does your organization identify the key opportunities for quality
improvement within your quality and compliance processes to ensure
compliance with FDA quality requirements?
6. What, if any, supply chain management technologies do your organization use
to address key barriers to integrating FDA product quality requirements into
your product quality metrics?
7. What are the strategies used by your organization to monitor quality
compliance throughout products’ life cycles?
8. What other information can you provide about the strategies used by your
organization to apply and integrate FDA’s quality compliance requirements
into your products’ quality metrics?
Conceptual Framework
The conceptual framework governing this study is Deming’s (1986) strategic
models for developing and implementing quality. Although Deming’s quality
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management theories are based on prior research by Taylor and Stewart, Deming is the
theorist responsible for four major quality implementation theories: (a) 14 points of top
management; (b) seven deadly diseases that management must cure; (c) plan, do, study,
act; and chain reaction quality implementation theories (Deming, 1986; Hackman &
Wageman, 1995; Quality Council of Indiana, 2007). However, six of Deming’s 14 points
for quality implementation were expected to closely apply to this study:
1. create consistency of purpose for improving products and services;
2. adopt the new philosophy;
3. cease dependent inspection to achieve quality;
4. improve constantly every process for planning, production, and service;
5. adopt and institute leadership; and
6. remove barriers that rob people of pride of workmanship, and eliminate the
annual rating and merit system.
Though other theorists such as Juran and Gryna (1988) favored a more structured
approach to implementing quality control, Deming’s 14-point quality implementation
theory applied to this study. As Munechika et al. (2016) opined, Deming’s 14-point
quality implementation theory is appropriate for developing and implementing quality
compliance strategies for use in mitigating costs that may arise from product quality
failures. Deming’s 14-point quality implementation theory provided a viable and robust
study platform to explore the strategies used by quality compliance managers in the
biotech industry to integrate and apply FDA quality compliance requirements into their
products’ quality metrics.
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Operational Definitions
Biologics: These are sugars, protein, or nucleic acids or a combination of these
substances or living entities such as cells and tissues that are produced by biotech
methods and gene-based cutting-edge technologies (Strauss & Borenstein, 2015).
Feedback loop: Feedback loop is the transmission pathway of cause-and-effect
information sequence (Strauss & Borenstein, 2015).
Good manufacturing practices: Good manufacturing practice (cGMP) refers to
the regulated FDA rules that provide for systems that ensure proper design, monitoring,
and quality of manufacturing processes and facilities (Hadjul & Kolinska, 2016).
Quality strategy implementation techniques: Quality strategy implementation
techniques are the techniques for selecting a supply chain quality implementation strategy
(Strauss & Borenstein, 2016).
Quality control samples: Quality control samples are the small product
specifications used to assess the precision and accuracy of an assay and the stability of
the samples (FDA, 2018).
Risk mitigation: Risk mitigation is the level of exposure to organizational
uncertainties that a leader must understand and be able to efficiently manage to create
values without undermining organizational values (Strauss & Borenstein, 2015).
Supplier risk metric: Supplier risk metric is a designated system of calculating
inherent risks within a supplier that may create quality issues down the supply chain
(Hadjul & Kolinska, 2016).
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Supply chain quality responsiveness: Supply chain quality responsiveness is the
promptness to which supply chain quality managers address quality issues within the
supply chain network (Sharma et al., 2018).
Supply chain quality risk management: Supply chain quality risk management is
the simple but clear and concise process of creating and managing risks throughout the
supply network (Hadjul & Kolinska, 2016).
Assumptions, Limitations, and Delimitations
Scholarly inquiries often address public views, perceptions, and realities through
analysis, values, and assumptions (Denzin, 2012). Strauss and Borenstein (2015) noted
that the procedures of qualitative studies may be imprecise in comparison to a
quantitative study because qualitative research focuses on understanding the experiences
and observations of the target population. Therefore, the targeted population behaviors
and practices are drawn from assumptions.
Assumptions
In a research study, assumptions are statements the researcher believes to be true
and valid though these statements may not have support (Yin, 2017). In a qualitative
study, key assumptions may form the basis upon which the researcher begins the study
(Yin, 2017). In the current qualitative study, I assumed that the participants would answer
all interview questions honestly and truthfully and that the participants would honestly
share their understanding and processes through which they form their quality
compliance practices. I also assumed that the participants’ experiences related to quality
compliance strategies would adequately describe the phenomenon under exploration.

10
Further, I assumed participants had experience in FDA quality compliance
processes and could articulate their experiences related to the research problem. I
assumed the information given was bias free. Also, I assumed the participants would
provide information that was true and represented their actual experiences rather than
their guesses or expectations. A qualitative researcher should always identify emerging
themes and patterns from the data received to avoid researcher biases (Lichtman, 2017).
These assumptions lead to certain unavoidable research limitations.
Limitations
A limitation is a condition or restriction preventing the state of completeness
(Kirkwood & Price, 2017). Limitations in a study may restrain the transferability of the
findings. Also, a lack of peer-reviewed research material may limit the efficacy of a
research finding. Yin (2017) noted participants’ less than optimal responses and
individual biases as a research limitation may influence the research reliability and
validity. One limitation of the current study was the decision to use only two sites. This
limitation could have negatively impacted the research reliability because it limited the
number of participants who could have participated in the study. However, researchers
introduce delimitations to effectively complete the study (Yin,2017). The researcher
selects the research design that will accomplish the research goal and accepts limitations
that are necessary to attain the research goal (Noble & Smith, 2015). In the current study,
I selected a multiple case study design to mitigate possible research limitations.
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Delimitations
Delimitations are the research boundaries reflecting the conscious omission and
addition of elements during development of the research plan (Marshall & Rossman,
2016). Supply chain professionals, quality compliance managers, auditors, indirect
suppliers, and technical leaders participated in the current study. I explored how
organizations in the biotech industry develop and deploy their quality compliance
strategies. The research participants had 10–20 years of experience in quality compliance
management, corporate governance, and operations management in the West region of
the United States.
Significance of the Study
The findings from the study may contribute to the current body of knowledge
related to how biotech quality compliance managers develop and implement quality
compliance strategies in response to FDA quality compliance requirements. Practitioners
may use the findings in the study to fill gaps in their current quality compliance
governance and strategies. The outcome of the study may serve as a reference guide for
quality compliance managers in selecting a strategy for FDA quality compliance
requirements. Quality compliance managers may use the recommendations in this study
when responding to FDA quality compliance visitations and citations.
Contribution to Business Practice
An explorative analysis such as this study may provide a clear and succinct
approach to business practice optimization such as earning quality compliance on the first
FDA inspection visit. This study may provide practitioners with strategies for developing
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and implementing quality compliance measures in response to FDA product quality
requirements. Practitioners may use the outcome of this study to mitigate the cost of FDA
product quality noncompliance enforcement.
Implications for Social Change
The implementation of the strategies discussed in the study may reduce drug
shortage of urgently needed biopharmaceutical drugs. The results of the study may lead
to growth in the U.S. economy by improving efficiencies in the biopharmaceutical
industry. Growth in the biopharmaceutical industry may result in job creation and
employment opportunities for Americans who work in biotech companies.
A Review of the Professional and Academic Literature
This literature review resulted from an exploration of peer-reviewed articles,
government regulations, and business books that related to the research question
addressing the strategies used by quality compliance managers in the biotech industry to
apply FDA quality compliance requirements in their products’ quality metrics. The
conceptual framework for the examination of the research question consisted of
Deming’s (1986) strategic models for developing and implementing quality.
Application to the Applied Business Problem
There was a gap in the available literature for supply chain quality management
strategies used by quality compliance managers in the biotech industry to attain FDA
product quality compliance. I did not find any literature that directly addressed the
research question. To conduct an effective review of the literature addressing the research
topic, I extended the search to include all terms that described processes and practices
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used by quality compliance managers in the biotech industry to formulate strategies to
attain FDA quality compliance. Researchers used terms such as compliance metrics,
regulatory compliance, process improvements, and monitoring to describe some
organizational practices used by quality compliance managers in the biotech industry to
formulate strategies in response to FDA product quality requirements (Giri & Sarker,
2017; Halldorsson et al., 2015; Kirovska et al., 2016). The literature review covers
compliance metrics, process improvements, and monitoring related to practices that
describe quality compliance managers’ activities directed at FDA quality compliance
requirements.
The literature review begins with an overview of Deming’s (1986) strategic
models for developing and implementing quality as the conceptual framework of the
study, followed by a review of contrasting and supporting quality management theories.
The literature review continues with an analysis of the U.S. regulatory and public health
policies. Further, I explore the FDA’s quality regulatory policy by examining the FDA’s
cGMP. Next, I address theories, concepts, and practices relevant to the study of FDA
quality compliance requirements: (a) quality assurance role in the biotech industry, (b)
government policies and the complexity of the biopharmaceutical delivery systems, and
(c) government policies and the adverse effects on the biotech product quality outcomes.
Academic Source Utilized to Conduct the Review
In support of this study, I reviewed a collection of peer-reviewed articles, books,
and government reports. I obtained peer-reviewed articles by searching academic
databases available in the Walden University library using the following search terms:
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Porter’s value chain, Deming management theory, supply chain quality management
techniques, biologics and quality compliance, quality process improvements, FDA quality
compliance citations, and supply and logistics integration. The databases I used were
Academic Search Complete, Business Source Complete, Science Direct, Life Sciences,
Politics & Government, and Social Science Citation Index.
Keywords, Phrases, and Terminologies
I used the following keywords, terminologies, and phrases when searching
reference databases for the literature review: biotech product quality compliance metrics,
FDA product certification metrics, FDA quality compliance requirement for the biotech
industry, supply chain management strategies in the biotech industry, FDA product recall
requirements in the biotech industry, and quality management strategies in the biotech
industry.
Diversity of Literature Sources
The research topic required the incorporation of numerous government agency
publications, bylaws, congressional hearings, and federal legislation. There was a need to
assess and compare government regulatory requirement documents with industry
practices related to FDA product quality compliance requirements. Also, I reviewed
academic and professional organizations’ viewpoints and opinions.
Conceptual Framework: Deming’s Quality Management Theory
In this study, I used Deming’s (1986) management theory as the conceptual
framework for exploring the strategies quality compliance managers in the biotech
industry use to integrate FDA product quality compliance requirements into their
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products’ quality metrics. Deming’s quality management theory has four major quality
implementation theories: (a) 14 points of top management; (b) seven deadly diseases that
management must cure; (c) plan, do, study, act; and (d) chain reaction quality
implementation theories (Deming, 1986; Hackman & Wageman, 1995; Quality Council
of Indiana, 2007;). Six of Deming’s 14 points for quality implementation closely applied
to this study:
1. create consistency of purpose for improving products and services;
2. adopt the new philosophy;
3. cease dependent inspection to achieve quality;
4. improve constantly every process for planning, production, and service;
5. adopt and institute leadership; and
6. remove barriers that rob people of pride of workmanship, and eliminate the
annual rating and merit system.
Munechika et al. (2016) opined that Deming’s 14-point quality implementation theory is
appropriate for developing and implementing quality compliance strategies for use in
mitigating costs that may arise from product quality failures. Deming’s 14-point quality
implementation theory was appropriate to explore the quality management strategies used
by biotech quality compliance managers to integrate and apply FDA product quality
compliance requirements into their products’ quality metrics.
Create Consistency of Purpose for Improving Products and Services
Consistency of purpose as a quality improvement strategy is one of the most
important aspects of quality improvement strategies. One of the core components of
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Deming’s (1986) 14-point quality implementation theory is create consistency of purpose
for improving products and services. Other quality research and implementation experts
agreed that consistency of purpose in quality implementation is at the core of any
process, product, or service quality implementation (Smith & Rupp, 2016). Quality
compliance managers should develop quality management strategies that are resilient to
maintain consistency. According to Fawcett et al. (2016), consistency in product and
service quality implementation guidelines and strategies improves stakeholder confidence
in the quality implementation processes. Quality improvement strategies may take
different forms, but consistency remains an important aspect in developing a sustainable
product and service quality. Smith and Rupp argued that consistency in the quality
implementation strategies within the organization continuously improves product quality
outcomes. Deming’s 14-point quality implementation theory and the core component of
creating consistency of purpose for improving product and services quality could help
quality compliance managers within the biotech industry create consistency in product
and service quality implementation. Further, consistency of purpose should also form part
of the organization’s new product quality improvement philosophy. Smith and Rupp
noted that consistency of purpose should be a core part of the organization’s standard of
operation and should form part of the organization’s new philosophy.
Adopt the New Philosophy
Organizations create and adopt a new quality philosophy to attain sustainable
quality implementation strategies. Deming (1986) noted that organizations must move
past the notion of seeing quality improvement as a new periodic exercise but should
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create and adopt the new quality implementation strategies within the organization as the
new organization’s philosophy. The adopted strategy becomes an integral part of the
organization’s overall quality mission. The adoption of quality implementation as a new
organizational philosophy by everyone within the organization is key to quality
improvement within the organization (Smith & Rupp, 2016). The inability to adopt
quality implementation as the organization’s new philosophy may impede quality
improvement strategies. Quality improvement as a onetime effort is not sustainable and
may be more costly in the long run (Deming, 1986). In the 14-point quality
implementation management theory, Deming argued that failure to adopt quality
implementation as an organizational theory creates management chaos and defects within
the management, planning, and production processes. To avoid such failures, managers
within the biotech industry may adopt a new philosophy of quality implementation in
integrating FDA quality product quality compliance requirements into their products’
quality metrics.
Improve Constantly Every Process for Planning, Production, and Service
The constant improvement of processes for planning, production, and service
aspects of Deming’s (1986) quality improvement strategies is relevant to product quality
improvement requirements in the biotech industry. Challener (2020) stated that process
improvement is a fundamental component of quality improvement in product
manufacturing. Dittes et al. (2016) agreed but noted that in instances when changes
would delay quality implementation, consistency is required, and process may not be
improved. However, other quality implementation practitioners agreed that continuous
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quality process improvement planning creates a quality metric that manufacturers in any
industry can use to improve product quality requirements (Dittes et al., 2016; Vellema et
al., 2016). The biotech industry as a manufacturing industry could use constant process
improvements to integrate and apply full FDA product quality requirements into their
products’ quality metrics. Standing et al. (2016) opined that continuous process
improvement is directly connected to process and planning improvement implementation.
The requirement for constant process and production planning may help eliminate
manufacturing quality errors that are costly (Stoica & Brouse, 2017).
By adopting Deming’s (1986) recommendation to improve constantly every
process for planning, production, and services, quality compliance managers in the
biotech industry may develop an effective quality management strategy to integrate and
apply full FDA product quality compliance requirements into their products’ quality
metrics. Vellema et al. (2016) argued that this aspect of Deming’s quality management
strategy is applicable in any manufacturing or service setting. The biotech industry as a
manufacturing industry could adopt and implement Deming’s quality implementation
theory without dependence on inspection and certification, which is a common practice in
the industry.
Cease Dependent Inspection to Achieve Quality
Though inspection is an integral part of the FDA regulatory regime, Deming’s
(1986) 14-point quality management theory requires little or no reliance on inspection to
achieve product or process quality. The quality implementation process is the
engagement of an active culture of quality and process improvement without the reliance
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on inspections (Deming, 1986). Reliance on inspection as a quality process improvement
strategy may impede innovation and continuous improvement (Pinto & Winch, 2016).
Reliance on inspection is discouraged to avoid creating a culture of reliance on
inspection, which upends a philosophy and culture of quality adherence (Ferreira, 2017).
Ferreira argued that learned organizational cultures are more effective in implementing
practices such as quality implementation compared to practices that are dependent on
other activities such as inspections. Further, other researchers have opined that reliance
on inspection to achieve quality requirement may create an environment of delay, chaos,
and lack of management response to change and process improvement requirements
(Belschak et al., 2016; Gunia & Kim, 2016).
Ferreira (2017) noted that dependence on inspection creates a work environment
that hinders employee motivation. Dependence on inspection creates delay in process
(Gunia & Kim, 2016). Ferreira further stated that quality requirement should form the
operational structure upon which the organization’s quality philosophy is based. Also,
Wu (2017) opined that developing a quality philosophy improves quality compliance
within the organization. Dependence on inspection is not enough. Organizations should
develop a philosophy of quality compliance and adopt quality leadership that ensures the
creation of a culture of quality compliance, not reliance on inspection (Gunia & Kim,
2016). By adopting this philosophy of compliance, the biotech industry may be able to
adopt and institute quality compliant leadership within the industry that may help develop
strategies to integrate and apply FDA quality compliance requirements into their
products’ quality metrics.
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Adopt and Institute Leadership
To integrate and apply FDA product quality requirements into their products’
quality metrics, organizations in the biotech industry must set an organizational tone of
quality that runs through the entire management structures (Wu, 2017). By adopting
organizational leadership that is quality oriented, an organization sets a tone of quality
implementation and improvement (Belschak et al., 2016). Further, an organization can
implement quality changes that improve overall quality performance within the
organization (Belschak et.al., 2016). Escoffery et al. (2018) argued that quality
implementation starts with the organization’s leadership capability as leadership defines
the quality metric of the organization. Whereas leadership sets the quality implementation
mandate, Wu (2017) opined that leadership must do more than lay down the rules; they
also must lead by example. That is one reason why Deming (1986) opined that quality
improvement within the organization requires leadership with a quality improvement
mindset. Quality leadership provides a roadmap for continuous quality improvement
(Wu, 2017). Wu further noted that, organizations through adopted leadership must
incorporate a philosophy of total quality management.
Organizations with quality conscious leadership creates an organizational culture
of total quality adherents (Green et al., 2012). Smith and Rupp (2016) noted that
management commitment is required to implement total quality goals. Smith and Rupp
argued that organizations must select quality leadership champions within the
organization to set the pace for a culture of quality within the organization. Escofferry et
al. (2016) argued that, to create a culture of quality, the organizations must select quality
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champions as leaders who would set the pace for the entire organization. Goedhuys and
Sleuwaegen (2016) agreed. Goedhuys and Sleuwaegen noted that when leadership sets
the pace, the entire workforce gets involved and pursues quality implementation as part
of their work commitments. Organizations within the biotech industry may integrate and
apply full FDA product quality compliance requirements into their products’ quality
metrics by adopting Deming’s adopt and institute leadership quality management
strategy. Companies in the biotech industry may use this theory to set up leadership
responsibilities to remove all instituted forms of barriers to quality implementation within
their organizations.
Remove Barriers That Rob People of Pride of Workmanship and Eliminate the Annual
Rating and Merit System
Workmanship pride is a core factor in instituting total quality management within
an organization. Feelings of humiliation and other morale issues such as lack of
information, work-life balance and lack of incentives create barriers to quality
improvement within the organization (Deming, 1987). Whereas employee recognition is
encouraged as a form of employee motivation, improperly managed employee motivation
may create a barrier to quality improvement strategies within an organization (Fida et al.,
2016; Golparvar, 2016). Accordingly, Wu (2017) argued that quality implementation is a
shared responsibility between management and employees. Also, Wu noted that quality
implementation is a shared responsibility between management and employees. Other
researchers agreed and opined that merit and recognition should be collectively shared as
quality management is a collective responsibility. (Fida et al., 2016; Golparvar, 2016).
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However, Harold et al., (2016) argued that individual recognition should be given
when an employee excels in quality management commitment. Wu (2017) agreed but
noted that recognition should not discourage but motivate the workforce. Deming’s 14point for quality implementation theory is supported by recent research as Deming noted
that, for any organizational quality requirement strategy to be successful, management
must motivate by removing barriers that robs employees of the workmanship and effort
needed to maintain set quality standards. Management should emphasize workmanship
pride as a core factor in instituting quality management strategies within the organization
(Deming, 1987). Porter’s value chain theory supports this view.
Porter’s Value Chain Model
Deming’s quality management theory forms the conceptual framework of this
study. However, Porter’s value chain theory aligns with Deming’s quality management
theory. Quality compliance managers, in the biotech industry, may integrate and apply
FDA product quality compliance requirements into their products’ quality metrics by
adopting Porter’s value chain model. Koc and Bozdag (2017) described the identification
of processes and activities for the purpose of improving quality as a core component of
Porter’s value theory. Further, Porter (1985) noted that processes are all activities such as
may include communication and customer engagement. Quality compliance managers,
within the biotech industry, may integrate and apply FDA quality compliance
requirements into their products’ quality compliance metrics by identifying activities and
processes that creates product quality compliance issues within their organizations. Porter
noted that business leaders may use his generic value model to develop strategies within
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their own industry to gain competitive advantages by identifying activities that impede
value creation. This means that business leaders in the biotech industry could adopt
Porter’s value chain model to improve product quality compliance and avoid FDA quality
noncompliance citations. Like Deming’s management theory, Porter’s value chain model
could form the theoretical foundation for exploring the strategies used by quality
compliance managers, in the biotech industry, to integrate and apply FDA product quality
requirements into their products’ quality metrics.
Porter’s value chain model may form the basis for quality improvement within the
biotech industry. McPhee (2015) noted that Porter’s value model is used by organizations
to create value by improving every process within the value chain. Porter’s value chain
model has been used as the foundation for a variety of qualitative and quantitative studies
(Cygler & Debkowska, 2015; Koc & Bozdag, 2017; McPhee, 2015). McPhee argued that
manufacturers could use Porter’s value chain model to improve product quality by
identifying the areas where defect exist within the myriad of manufacturing activities. By
contrast, Cygler and Debkowska noted that, Porter’s value chain model is applicable and
useful in the service industry. However, Koc and Bozdag deferred and argued that
Porter’s value chain is applicable in a manufacturing business setting. Similarly, Prajogo
et al., (2016) argued that quality practitioners could use Porter’s value model to improve
logistical processes and create a competitive advantage. Though the conceptual
framework of this study is based on Deming’s management theory, Porter’s value chain
theory, like Simons’s Levers of Control theory could form the conceptual framework of
this study.
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Simons’s Levers of Control Theory
Simons’s lever of control (LOC) theory of strategic management is a supportable
theoretical foundation for this study. Like Deming’s strategic management theory, other
researchers identified LOC as a strategic management tool (Martyn et al., 2016).
According to Simons (1995), LOC theory consists of four major structures: (a) belief
systems and core value, (b) boundary systems and risk to avoid, (c) interactive control
systems and strategic uncertainty, and (d) diagnostic control systems and critical
performance variables. Peters (2019) noted that, the biotech industry need to mitigate the
crisis of noncompliance with a culture of compliance. Also, in support of these LOC
strategic variables, Peter noted that compliance managers in the biotech industry will
attain FDA compliance by effectively managing critical quality performance measures
within the manufacturing process. Risk avoidance is a core part of LOC’s theory of
strategic management and could form the basis for exploring the strategies used by
quality compliance managers, in the biotech industry, to integrate and apply FDA quality
compliance requirements into their products’ quality metrics. Also, Simons highlighted
the examination of control systems and critical performance variables are a core tenet of
Simmons’s LOC strategic management theory. Peters argued that leaders in the biotech
industry should develop FDA quality compliance strategies to manage activities that may
create risk.
Deming’s strategic management theory and Simons’s LOC theory could be used
as the conceptual frameworks for this study. This is the case because, quality
improvement forms the basis of both theories. These theories may provide insight into
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how compliance managers, in the biotech industry, integrate and apply FDA product
quality requirements into their products’ quality metrics. In contrast, Social Learning
Theory may not provide an effective theoretical foundation for exploring the strategies
used by quality compliance managers, in the biotech industry, to integrate FDA quality
compliance requirements into their products’ quality metrics.
Social Learning Theory
Social learning theory (SLT) is not an appropriate conceptual framework to
explore the strategies used by quality compliance managers in the biotech industry to
integrate FDA quality compliance requirement into their product quality metrics. Under
the SLT theory, human behavior is a continuous interaction between cognitive, behaviors,
and the human environmental elements (Bandura, 1978). Accordingly, Hartmann and
Doree (2015) argued that SLT theory means humans learn by observing others and by
obeying environmental factors and not rules. Bandura developed the SLT theory in a
study while researching how to cure phobias. The focus of this study is to explore
strategies and not behaviors. The SLT theory focuses on behaviors and how humans learn
(Horsburgh & Ippolito, 2018).
Therefore, SLT theory is not an appropriate conceptual framework for the
exploration of strategies used by compliance managers, in the biotech industry, to
integrate and apply FDA quality compliance requirements into their products’ quality
metrics. However, several researchers have applied SLT in closely related studies. Brown
et al., (2005) used SLT theory as the conceptual framework for studying leaderships and
leader’s ethical behavior in a manufacturing setting. The SLT concept of modeling
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requires that people learn behavior through observation, imitation, and identification
(Bandura, 1978). The SLT theory would be appropriate in exploring why employees look
to managers for motivation in work-related matters (Kalshoven, van Dijk, & Boon,
2016). Reinforcement of ethical standards and ethical decision-making are two means via
which leaders can make an impact on employees’ moral principles (Kalshoven et al.,
2016).
In contrast, Deming’s quality management theory provides a robust platform for
exploring strategies used by quality compliance managers, in the biotech industry, to
integrate and apply FDA quality compliance requirements, into their products’ quality
metrics. One core component of Deming’s management theory is that management
should remove barriers such as lack of information needed to formulate quality
requirement strategies. Managers in the biotech industry may remove such barriers by
providing employees with current and relevant regulatory information needed to
effectively incorporate government quality requirements (Peters, 2019).
U.S. Regulatory and Public Health Policy
The United States’ Food and Drug Administration (FDA) is responsible for a
large portion of the regulatory regimes that governs the US biopharmaceutical industry
(Chabner, 2011). Biopharmaceutical policy is a sub-category of the pharmaceutical health
policy with the responsibility of developing drug development process (Woodcock &
Wosinka, 2013). According to Chabner, pharmaceutical policy manages the factors of use
and delivery and qualifies the components of drug formularies which shapes the
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biopharmaceutical industry landscape mostly through regulatory policies by the Food and
Drug Administration (FDA).
U.S. Food and Drug Administration
Before 1980 the FDA acted mostly as a protectionist regulatory entity in its
approach to drug approvals and manufacturing inspections (Pazhayattil et al., 2019).
Before 1980 the widespread AID pandemic made the FDA aggressive in response to
public outcry for protection from the use of unsafe and contaminated clinical products by
drug manufacturers (Chabner, 2011). Pazhayattil et al., noted that the U.S government
through administrative orders and other legislations supported the FDA’s protectionist
approach however, after 1980 the FDA’s senior leadership changed its position from
protectionism to process quality regulation. The FDA through The Center for Biologics
Evaluation and Research (CBER) began to protect the public through responsible safety,
purity and potency regulations of biologics and other biopharmaceutical products
(McLaughlin & Skoglund, 2015).
Center for Biologics Evaluation and Research
The FDA’s Center for Biologics Evaluation and Research (CBER) is tasked with
the responsibility of providing the US biopharmaceutical industry and the public with
regulatory guidance to ensure the safety, purity, potency, and effectiveness of biological
products such as blood and blood products, tissues, gene therapies, diagnosis, and the
treatment of human diseases (FDA, 2018). Dorsey et al., (2009) noted that CBER
research activities creates the FDA’s regulatory requirements. For instance, through
CBER annual guidance documents, the center provides guidance to biopharmaceutical
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manufacturers on issues that relates to product quality design, production and
manufacturing and testing of regulated products (FDA, 2018). In July 2020 the FDA
through CBER issues guidance on The Safe Importation Action Plan which provides
industry practitioners with the FDA’s Food, Drug, and Cosmetic Act (“FD&C Act”)
section 804 to authorize demonstration projects to allow importation of drugs from
Canada. Also, in January 2020, CBER issued Human Gene Therapy for Hemophilia:
Guide for Industry. This document provides biopharmaceutical quality practitioners with
specific guidance on how to attain FDA quality compliance requirements for the
manufacture of Gene Therapy products used for the treatment of any bleeding disorders
other than hemophilia A and B, because of the unique nature of those bleeding disorders
(Peters, 2019). The FDA regulatory compliance regime also includes guidance from the
Center for Drug Evaluation and Research (CDER). Drugs that are not biologics are under
the administration of CDER.
Center for Drug Evaluation Research
The FDA’s Center for Drug Evaluation Research (CDER) provides regulatory
compliance requirement for the manufacture of most drugs as defined in the Food, Drug,
and Cosmetic Act. Although, there are some biological products that are also legally
considered drugs, these categories are covered by the Center for Biologics Evaluation and
Research (FDA, 2018). The CDER, through the Office of Drug Security, Integrity, and
Response (ODSIR) provides the biopharmaceutical industry with guidance on the global
supply chain security and the minimization of consumer exposure to unsafe, ineffective
and poor-quality drugs (FDA, 2018). Guidance from the CDER provides experts in the
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field of drug manufacturing with clear approach to maintaining FDA quality
requirements (Arab et al., 2017). Similarly, while discussing the role of the CDER in
providing regulatory compliance guidance to industry, Conrad et al., (2017) noted that
the CDER helped in providing industry with research breakthrough for therapy
designation. Conrad et al., noted that the CDER provides quality compliance officers
with drug certification process guidance and compliance strategies in the
biopharmaceutical industry in conjunction with the FDA as well as leads the FDA’s
implementation of the Drug Supply Chain Security Act and its policies which ensures
drug quality and risk information regarding product recalls.
Drug Quality and Security Act
The U.S Congress enacted the Drug Quality and Security Act of 2013 on
November 27, 2013 with Title II of DQSA, the Drug Supply Chain Security Act
(DSCSA) (Elliasen, 2020). Elliason pointed out that the FDA uses this Act to provide
quality compliance managers with steps to build an electronic, interoperable systems to
identify and trace quality component of prescription drugs in the United States.
Manufacturers also use the Act to control quality because the Act highlights ways to
remove counterfeit, stolen, contaminated, or otherwise harmful drugs from the
manufacturer’s supply chain. This is a regulatory framework to help manufacturers meet
FDA’s quality compliance requirement. According to Elona and Albert (2016), the Drug
Supply Chain Act of 2013 will also improve detection and removal of potentially
dangerous drugs from the drug supply chain to protect U.S. consumers.
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However, Haeyoung (2017) argued that the DSCSA had not been successful in
providing compliance managers in solving product quality compliance issues as it
compounds some compliance issues such as documentation processes. Likewise,
Dinkelaker (2016) agreed and opined that the Act provides a false sense of safety to
consumers but does very little to help quality compliance managers meet FDA quality
requirements. Although the DSCSA may not answer all the compliance questions for
quality compliance managers within the biotech industry, the Act provides a useful
guidance. As Eliasen (2020) noted, the Act provides compliance managers with a useful
start towards FDA regulatory compliance efforts. Under the DSCSA the FDA established
a national licensure standard for wholesale distributors and third-party logistics providers,
and requires these entities report licensure annually to the FDA. The FDA’s quality
regulatory regime remains a starting point for any quality compliance effort in the biotech
industry (Eliasen, 2020). The FDA’s quality regulatory regime forms the backbone of the
biopharmaceutical quality compliance framework.
FDA’s Quality Regulatory Policies
The FDA’s drug regulatory policy provides guidance, structure, and regulates the
pharmaceutical industry (Peters, 2019). However, some researchers opined that the FDA
is still behind in developing a proper cadence of communication (Dorsey et al., 2009;
Kweder & Dill, 2012; Ventola, 2015). This may be the case, but not always. As Elona
and Albert (2016) opined that the FDA positively influenced healthcare policies in the
United States and many other countries around the world. Further, Eliasen (2020) advised
that drug manufacturers should seek more FDA intervention than less because the FDA
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protect lives, improve drug quality, and prevent drug shortages in the United States.
Eliasen further argued that the FDA protects the U.S healthcare system from nations with
little or no quality regulations such as China and India. Kweder and Dill agreed and noted
that the FDA has come a long way, and in the process developed more regulatory
practices that has helped to strengthen the US biopharmaceutical quality compliance
effort.
FDA’s Current Good Manufacturing Practices Requirements
Product quality standards, in the biopharmaceutical industry, are set by the FDA
using the guidelines as stipulated in the agency’s cGMPs quality guidelines. The FDA
using the cGMPs guidelines provides manufacturers with quality standards to meet
product quality standards in the United States (Peters, 2019). Lincoln (2012) identifies
the need for a quality management system as set forth by the Food and Drug
Administration (FDA) within the Code of Federal Regulations. The current Good
Manufacturing Practices (cGMP) is set forth in the Quality Systems (QS) regulation
under sections 520 of the Food, Drug and Cosmetics (FD&C) Act of 1938. The FD&C
Act of 1938 gave the FDA power to administer quality requirements for food, drugs and
devices in the United States (FDA, 2018). The cGMPs are loosely written quality
standards that allows each organization to set, develop and implement quality systems,
write standard operating systems, and develop organizational forms for documenting
compliance in accordance with the cGMPs guidelines (Peters, 2019). Wiggins et al.
(2019) noted that, the cGMPs are meant to be easy to follow common sense guidelines
that ensures safety and effectiveness of products delivered to members of the public as
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product end users. Other researchers agreed the cGMPs standards are easy to follow, but
noted that, it is the product manufacturer’s responsibility to adopt the recommendations
even when they appear to be cumbersome (Chabner, 2011; Schneppe, 2019). However,
Pazhayattil et al. (2019) opined that some parts of the cGMPs are too rigid to adopt in
certain manufacturing scenario.
Although many manufacturers consider the requirements of the FDA’s cGMPs
standards rigorous, Peters (2019) noted that other countries worldwide are beginning to
emulate the quality management standards set forth by the FDA in the cGMP. The United
States quality management requirements is a pace setter worldwide (Lincoln, 2012). The
FDA’s cGMPs provides biologics product manufacturers within the biotech industry with
details of what a qualified quality management system should comprise (Wiggins et al.,
2019). The cGMPs quality management guidelines provide manufacturers with a
reference when designing their quality metrics, such as the proper documentation of
processes associated with the product manufacturing procedure (Schnieppe, 2019). For
example, if an organization fails to document a quality procedure in the manufacturing
process, the FDA will conclude that the manufactured product is defective, adulterated
and does not meet the FDA’s quality requirement and thereby subject to product recall,
and in some cases, closure of the manufacturing facility (Wiggins et al.,2019). In a less
severe instance of cGMPs quality standard non-compliance, the FDA may issue an FDA
Form 483 listing all observations, or may issue a warning letter (Peters, 2019).
An FDA form 483 is a report issued by the FDA to organizations in which the
FDA documents concerns and observations for one of three reasons: (a) the organization
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lacks proper procedures for regulated areas within the manufacturing facility, (b)
organization has FDA approved procedures but fails to follow the procedures, or (c)
organization lacks sufficient documentation evidencing proper implementation of
procedure (Mirasol, 2020). Mirasol noted that he most common reason for FDA form 483
Observations and Warning Letters in the biotech industry is the lack of quality
compliance procedure documentation. The lack of a culture of compliance accounts for
other FDA form 483 Observation and Warning Letter issuance in the biopharmaceutical
industry (Mirasol, 2020). The inability, by the quality compliance department to develop
clear and concise written procedures in conjunction with other departments such as
collaborations with quality assurance department, production department and information
technology department also accounts for a reasonable number of FDA citations (Peters,
2020).
Poor laboratory procedure is the most common recurring theme in FDA warning
letters (Wiggins & Albanese, 2019). Wiggins and Albanese further stated that, in many
cases, either procedure is nonexistent, or the procedures are not properly documented.
Other reasons for FDA 483 observation and warning letters includes equipment
mismanagement issues such as lack of inspection and cleaning records, lack of
maintenance documentation and improper handling of final products (FDA, 2018; Peters,
2020; Wiggins & Albanese, 2019). These research findings are relevant to this study
because the current findings highlight the key issues faced by quality compliance
managers in developing a strategy to attain FDA quality compliance regulatory
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requirement within the U.S biotech industry. As noted by Wiggins et al. (2019) Quality
assurance gives rise to a successful quality compliance in an organization.
FDA’s Response to Biopharmaceutical Quality Compliance Failures
The FDA has developed detailed recommendation for product quality compliance
for the U.S biopharmaceutical industry. Kweder and Dill (2012) discussed in their
empirical study the FDA’s response to biopharmaceutical quality issues and provides an
analysis of the strategies adopted by the agency in developing and coordinating quality
metrics as outlined in the revised cGMPs recommendations. The authors noted that,
whereas the FDA has created rules developed and administered by CBER, the biotech
industry is yet to gain all the benefits promised by the FDA. Quality failures in the
biotech industry is cause by internal failures, not the FDA’s inability to regulate the
industry. Peters (2019) opined that FDA guidelines are to help the biopharmaceutical
industry and not to hinder the industry. Accordingly, Kweder and Dill noted that since the
agency’s inception, it continued to work with drug manufacturers to avoid drug shortages
that may result from quality failures by providing annual guidelines.
However, Wiggins et al. (2019) concluded the FDA’s quality regulatory regime is
beginning to look like the agency’s pre-1980 approach as manufacturers within the
biopharmaceutical industry are unable to meet the quality compliance standards set by the
FDA through the applications of the cGMPs guidelines. In contrast, Peters (2019) noted
that the FDA’s cGMPs standards and recommendations are easy to follow whenever
industry practitioners develop a metric for administering the requirements of the cGMPs.
Quality compliance managers may efficiently adopt the cGMPs quality regulatory
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guidelines when designing a working quality compliance metric that follows the FDA’s
annual cGMPs guidelines. As Peters pointed out, the FDA annually improves the quality
compliance metrics for industry practitioners.
FDA’s Quality Improvement Process Recommendations
The FDA quality improvement recommendations provides the biopharmaceutical
industry with useful tools for addressing quality compliance issues such as quality
compliance documentation processes. Quality compliance recommendation enunciated in
the new FDA’s cGMPs standards affords quality compliance officers across the industry
with helpful tips and recommends that quality compliance officers in the
biopharmaceutical industry can rely on to meet regulatory product quality requirements
by the FDA (Peters, 2019). This is one way by which quality compliance officers may
take a more vigilant and responsive role in responding to quality issues within the
biopharmaceutical industry. Accordingly, Chabner (2011) discussed new efforts by the
FDA to renew and improve response to the call for inspection of new manufacturing
facilities. However, some researchers are of the view that the FDA’s compliance
requirement through the instrument of the cGMPs is not helpful. That is why Pazhayattil
et al. (2019) argued that the FDA’s current practices does very little to help in providing
industry practitioners with helpful quality compliance guidelines that practitioners could
consider as manufacturer friendly. It is important to note that, while Pazhayattil et al is
not alone, authors who held this view were in the minority. The view that, the FDA’s
effort in providing regulatory guidelines that are design to help the biopharmaceutical
industry with quality compliance requirements is in the majority. Hence Peters noted that
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the FDA’s effort is in the right direction as the agency’s cGMPs are easy to follow and
product manufacturers that are committed to quality compliance can effectively comply
with the FDA’s requirement for quality in the biopharmaceutical industry. For instance,
the FDA continue to improve quality compliance requirements by providing updated
cGMPs guidelines for practitioners to refer to and offer monthly and weekly updates for
steps, processes, and strategies for compliance (FDA, 2018). Also, many researchers are
of the view that the FDA’s regulatory guidelines help manufacturers comply with quality
standards and not to hinder manufacturing progress (Chabner, 2011; Kweder & Dill,
2012; Peters, 2019).
Quality Assurance Role in Product Quality Compliance in the Biotech Industry
Quality assurance when shared across departments creates a culture of
compliance. Joghee (2019) explains the importance of Quality Assurance in the
development and implementation of regulatory compliance strategies by discussing the
methods for engaging quality engineering systems to leverage and optimize product
quality assurance within the manufacturing process. Also, recent studies showed that,
quality assurance role in the organization, when incorporated across all departments, and
not left only with the quality assurance department, creates a significant improvement in
product quality outcomes (Anwar et al., 2016; Kharub, 2019). For instance, Joghee
opined that, to create a sustainable culture of quality, organizations must develop quality
interactions that span all areas of the organization. In the same vein, another scholar
noted that, management must foster an engaging relationship, centered around product
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quality compliance, with all employees and departments and not left only in the hands of
those who implement the quality requirements (Kharub, 2019).
To foster the inclusion of quality assurance into the quality compliance
commitment, researchers argued that organizations who use technologies to integrate
quality compliance requirements across departments improve product quality outcomes
better than those who did not (Reid, Hultink, Marion, & Barczack, 2016). Organizations
need technologies to implement data integration. Hence, Bajaj, Garg, Sethi, and Dey
(2019) noted that, technology enhanced collaboration between quality assurance and
quality compliance departments is inevitable to reduce quality failures. The efficient
collaboration between departments reduce cost by avoiding duplication of quality
compliance efforts within the organization (Baja et al., 2019). The use of technology to
enhance collaboration between departments such as quality assurance department and
quality compliance department is important in developing sustainable quality compliance
strategies within the biotech industry (Vaidya, Ganapathy, & Kumar, 2019).
The degree to which quality assurance plays an important role in ensuring
organizational quality compliance is determined by the tone set by upper management
within the organization (Harold, Oh, Holtz, Han, & Giacalone, 2016; Vadaya et al.,
2019). Harold et al. described environmental factors such as work cultures, work-life
balance and the work team structures, and overall management commitment as some of
the techniques used by management to instill a culture of quality assurance across all
departments within an organization. Organizations create a culture of personnel
motivation as a technique for encouraging employees to adopt a culture of quality
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commitment within the organization. Rubin (2012) opined that, encouraging and
motivating employees to incorporating product and process quality assurance
requirement across the organization gives employees significant insight into the product
being produced and the strategies employed. Motivating employees to embrace shared
quality assurance strategies across organization improves overall quality compliance
culture (Fida et al., 2015). In support of this view, Page et al., (2015) argued that
organizations need employee commitment across departments to make quality
compliance a shared responsibility across the organization. Further, when Quality
Assurance operates without interrelations with other departments such as operations,
production and quality compliance departments, product quality compliance risk
increases (Fida et al., 2015). However, Rubin noted that, in some instances, Quality
Assurance is sometimes viewed as an obstruction to production goal. Nevertheless, Page
et al., (2015) noted that the requirement to make quality compliance a shared
commitment within the organization is inevitable. Hence, according to Fida et al., (2015),
management must set the organization commitment tone for quality compliance within
the organization.
Government Policies and the Complexity of the Biopharmaceutical Delivery
Systems
The complexity of the U.S biopharmaceutical delivery system impacts product
quality compliance. McLaughlin and Skoglung (2015) noted that due to the delivery
complexity of the U.S biopharmaceutical system, there is a lack of academic research and
reservations within the product quality management systems as it relates to the
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biopharmaceutical delivery systems. The limit in academic research in the
biopharmaceutical quality management regime creates quality compliance issues which
contributes to the delay in product development (McPhee, 2015). Munechika et al.,
(2016) argued that globalization and the popularity of biopharmaceuticals contributed to
the complexity of the product manufacture and delivery systems. However, the FDA
provides new guidelines with more research and to mitigate the complex product delivery
system (FDA, 2018). However, management would develop individual practices to
mitigate the complex delivery systems and attain full FDA product compliance
requirements (Wang et al., 2016). The biopharmaceutical product delivery complexity
accounts for many quality compliance failures within the industry (McPhee, 2015).
Accordingly, Marisol (2020) discussed how the globalization and popularity of
biopharmaceuticals creates a degree of complexity for the FDA when designing
compliance requirements. The authors observed the inherent complexities in the
compliance requirement systems as it relates to communication between the FDA and
industry practitioners when developing product quality compliance requirements. In
contrast, Wang et al. argued that, beyond global process complexity, the FDA had not
developed a compliance requirement good enough to effectively regulate
biopharmaceutical product complex delivery systems. The FDA should not police
manufacturers but should continue to offer simple and attainable guidelines that U.S
biopharmaceutical manufacturers could rely on with certainty. According to the authors,
the government can make compliance easy by creating a local platform for U.S
manufacturers. The authors argued that by creating a local compliance platform without
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focus on the global market, local compliance is made easy for local U.S manufacturers.
Also, Janvier-James (2016) concluded that the solution to compliance in the
biopharmaceutical industry rest with the individual organizations and not the FDA’s
regulatory regime. Wang et al. suggested using management strategies such as
organizational changes and leadership training to implement FDA product quality
requirements within the organization. Wu noted that, rather than using draconian
regulatory strategies and creating increased violations and citations, the FDA could help
improve quality compliance by utilizing a collaborative working relationship with the
industry by developing a process of working collaboratively with the biopharmaceutical
industry to attain and improve compliance within the United States. Though the product
manufacture and delivery system are complex, Janvier-James concluded manufacturers
are responsible for compliance through personnel planning and training.
From a quality management theory perspective, McPhee (2015) theorized quality
management strategies as enunciated by Deming (1987) may provide industry
practitioners with the needed approach to applying and implementing quality
requirements in a very complex product delivery setting. Harold et al. (2016) agreed and
stated that, FDA noncompliance citation hinders the growth of the biopharmaceutical
industry. Other researchers had opined that, the application of quality management
strategies that relies on organizational culture of quality management will improve
compliance and reduce chaos resulting from lack of compliance (Harold et al, 2016)
Deming’s quality management theories applied in a complex manufacturing stetting may
provide respite growth and reduce failures resulting from lack of quality compliance
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(Deming, 1987). Additionally, as Janvier-James noted, organizations should train
employees on specific government regulations and policies that impacts the
organization’s efforts towards quality compliance.
Government Policies and the Adverse Effects on Biotech Product Quality Outcomes
Government quality regulatory policies, in some instances, have adverse effects
on product quality compliance efforts in the biotech industry. Some researchers agreed
that cumbersome and hard to follow quality regulatory policies accounts for majority of
the lack of compliance issues in the biotech industry (Giesecke, 2000). The contrasting
roles of the U.S Government in the development of the biotechnology industry is
undeniable (Deng, Hu, Pray, & Jin, 2019). Further, Harold et al. (2016) noted that, in
some cases, the FDA creates new quality compliance problems while developing
solutions to old quality compliance problems. Whereas Janvier-James (2016) argued that
quality compliance rests solely with the individual organization, the implication of
government policies such as the New Drug Application (NDA) processes and the Foreign
Investment Risk Review Modernization Act (FIRRMA) of 2018 are examples of
government policies that may have adverse effects on product quality compliance in the
United States (Deng et al., 2019).
New Drug Application Policy
The new drug application (NDA) policy is under the auspices of the Food, Drug,
and Cosmetics Act (FD&C) of 1938. The Act required pharmaceutical companies to
include only information relating to a proposed new drug’s safety. However, in 1962 the
FD&C Act require pharmaceutical companies to include evidence on the new drug’s
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effectiveness for its intended use and confirm that the new drug’s established benefits
outweighed its known side effects. The rigorous NDA process may have a negative
impact on drug quality compliance. Van and Pray (2019) argued that the NDA process as
administered by the FDA’s Center for Drug Evaluation and Research (CDER) is too
lengthy and may have a few lessons to learn from the legalization of Marijuana process
adopted by many states in the United States. The authors argued that the CDER’s use of
10 months to review new drug applications as only one phase of multi-steps process that
pharmaceutical companies must navigate in order to successfully bring a new drug to the
market is problematic. As Harold et al. (2016) opined, FDA’s policies such as the NDA
process may negatively impact investor’s commitment and interest in the biotech
industry. Other policies such as the Foreign Investment Risk Review Modernization Act
(FIRRMA) directly makes the biotech industry unattractive to foreign investors.
Foreign Investment Risk Review Modernization Act
In August 2018, Congress passed the Foreign Investment Risk Review
Modernization Act (FIRRMA) as part of the Fiscal 2019 National Defense Authorization
Act. FIRRMA may have a negative impact on product quality compliance by reducing
foreign investment in the biotech industry. FIRRMA broadened the scope and oversight
of the Committee on Foreign Investment in the United States (CFIUS) to include the
review of foreign investments in companies involved in critical biotech technologies
(Westbrook, 2019). Wakely and Indolf (2018) opined that the Act has an adverse effect
on foreign investment. The U.S government directed the Act at curbing investment in the
biotech industry from China, but the Act invariably has an adverse impact on venture
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capital (VC) investment in biotech. Under the FIRRM regulatory regime, foreign
investors are required to go through rigorous application reviews which required several
months of review time and very expensive legal fees before investing in the biotech
industry (Wakely & Indolf, 2018). According to Leiter, Caccia, Cruz, Hoffman, Gafni,
and Gerkin (2019), FIRRM Act may push US investors to foreign markets and create
shortage of essential drugs in the United States. The Council of State Bioscience
Association (CSBA) noted that, the bill could lead to a reduction in drug manufacturers’
revenues and may lead to a reduction of approximately eight to 15 new drugs coming to
market (Wakely & Indorf, 2018). The Act may indirectly impact new product patents as
biopharmaceutical patents are capital intensive projects.
America Invents Act of 2011
The America Invents Act (AIA) of 2011 provided the most extensive revision of
U.S. patent law in the past 60 years and may undermine innovation (Miyagiwa, 2015).
The Act is arguably one of the United States Patent and Trademark Office’s (USPTO)
most extensive guideline on Patents in the United States. According to Yelderman
(2019), the Act has too many unintended and unknowable consequences for innovators
who rely on the patent system to fund and protect their inventions. One significant impact
of the AIA is that it allows a party to challenge the validity of an already issued patent
before the USPTO. In discussing this aspect of the Act, Sipe (2019) argued that the Inter
Partes Review (IPR) and the Post-Grant Review (PGR) of the AIA have the most
significant negative impact for the biopharmaceutical industry.
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In contrast, other researchers opined the AIA created viable and safe patent
regime for the biopharmaceutical industry (Lingenfelter, 2015; Reis, 2012; Trilling,
2012). The AIA arguably protects SMEs patents from big pharmaceutical companies.
Lingenfelter noted that, under the new guidelines, stolen patents are registrable with The
USPTO before true owners could. Also, Sipe (2019) noted that, whereas the first-toinvent system to the first-inventor-to-file system is one positive aspect of the Act, the Act
in reality creates confusion and delays in certain instances when the agency and the court
fails to determine the true owner of a patent.
Transition
In Section 1, the chosen research method and design for this study is the
qualitative case study. The research population is five biotech quality compliance
managers in the West region of the U.S. These quality compliance professionals have 15
to 20 years of experience implementing FDA quality compliance requirements. The
conceptual framework for this study is Deming’s quality management theory. The
statement of the problem and study purpose is consistent with how quality compliance
managers perceive the challenges faced when responding to FDA quality regulatory
compliance requirements.
In Section 2, I described: (a) the role of the researcher, (b) the population and
sampling methods, (c) data collection and analysis techniques, (d) a description of the
research participants, and (e) explanation of the ethical research process. Further, section
2 contains a description of the research reliability and validity. Section 3 contains a
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detailed presentation of the research findings. In this section, I present recommendations
for actions as well as suggestions for future research study.
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Section 2: The Project
Purpose Statement
The purpose of this qualitative multiple case study was to explore the strategies
that quality compliance managers in biotech companies use to integrate and apply FDA
product quality compliance requirements into their products’ quality compliance metrics.
The target population consisted of five biotech quality compliance managers from three
biotech companies in the West region of the United States who had successfully
implemented strategies to integrate and apply FDA product quality compliance
requirements into their products’ quality compliance metrics. The findings of this study
may contribute to social change by providing the U.S. population with more rapid access
to urgently needed drugs and treatment. The findings from this study may also help to
mitigate FDA citation compliance violation cost incurred by the biopharmaceutical
industry, which is typically passed down to the public in the form of higher drug costs.
Role of the Researcher
In a qualitative research study, the researcher is responsible for the research
design, data collection, and data analysis (Denzin & Lincoln, 2015). According to the
National Commission for the Protection of Human Subjects of Biomedical and
Behavioral Research (1979), the researcher is also responsible for all ethical concerns
that may arise in the research process. As noted in the Belmont Report (National
Commission for the Protection of Human Subjects of Biomedical and Behavioral
Research, 1979), the researcher should always adhere to the core principles of respect for
persons as research participants. Doody and Noonan (2016) emphasized the importance
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of participants’ voluntary participation and informed consent as core ethical research
requirements. I obtained participants’ signatures in the informed consent form. Also, the
form contained a detailed explanation of the participants’ rights to accept, reject, or
withdraw consent at any time during the study.
Further, it is the researcher’s responsibility to promote the research validity by
ensuring and managing appropriate sample sizes and avoiding personal and participants’
bias (Yin, 2017). Yin noted that the researcher is responsible for selecting the research
design that fits the research purpose and accurately answers the research questions. I
obtained Walden University’s Institutional Review Board’s (IRB) approval and guidance
before contacting research participants. I encouraged the participants to explain their
professional views freely and adequately without any suggestions or leading questions
that may have caused personal bias to influence participants’ answers. Researchers use
qualitative research methods to gain deeper understanding of people’s or groups’
experience without the researcher’s bias (Fusch & Ness, 2017). As Marshall and
Rossman (2016) suggested, qualitative research questions may help the researcher
identify and manage personal biases prior to the interview. Therefore, collected data will
reflect the views of the participants and not the researcher’s personal views, experiences,
or expectations.
In this qualitative multiple case study, my role as the researcher was to explore
strategies used by quality compliance managers in the biotech industry to apply FDA
product quality compliance requirement in their products’ quality metrics. Researchers
use qualitative research methodology to gain deeper insight into the study topic (Yin,
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2017). Researchers use interview protocols to seek deeper understanding of practices and
scenarios (Jacob & Ferguson, 2015). In the current study, I used interview questions to
understand the strategies used by quality compliance managers to apply FDA quality
compliance requirements in their quality compliance metrics within their firms.
Participants
The eligibility criteria for the five quality compliance managers to participate in
the study were as follows: (a) employed in a leadership position with a biopharmaceutical
company in the West region of the U.S, (b) administration and development of supply
chain management strategies for quality compliance, and (c) demonstrated
implementation of successful quality compliance strategies in response to FDA quality
compliance regulatory requirements. In this study, purposive sampling was used to select
eligible participants working in the biotech industry. Purposive sampling provides the
researcher with informed and knowledgeable study participants (Fusch & Ness, 2017). In
the current study, quality compliance managers who had implemented quality compliance
strategies to apply FDA quality requirements were selected as participants.
I established a working relationship with the research participants by sending
emails and making phone calls when appropriate. I gained participants’ trust by
explaining the research overview and asking whether the participants were willing to
participate in the study. I provided my email contact information and asked the
participants to contact me at any time if they had any questions or needed clarifications at
any time during the study. I provided the participants with a detailed study overview such
as the problem statement, purpose, research questions, and interview questions.
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Further, upon IRB approval from Walden University, I asked the study
participants to review and return a formal letter of consent to me. This letter of consent
returned by the participants signified their interest in participating in the study through
their own free will. I also stated in the consent form that all participants were free to
withdraw their consent at any time during the study. Although voluntary participation
decreases participants’ response rate, Marshall and Rossman (2016) argued that voluntary
and willful participation decreases the pressure to fabricate responses. It is ethical to
ensure participants participate willfully and truthfully.
The ethical requirement to protect participants’ confidentiality is crucial to the
study’s reliability. As Yin (2017) opined, unethical data gathering undermines the study’s
reliability and validity. The measures to ensure ethical protection of participants’
confidentiality include but are not limited to (a) use of confidentiality forms, (b)
interview process approval by executive leadership, (c) a promise to respect participants’
privacy and/or the company’s confidential information, and (d) approval of the study
from the IRB (Walden University, 2015).
Research Method and Design
A researcher selects a research method and design that are appropriate for the
researcher’s study goals (Morse, 2015). My goal for this study was to understand the
strategies used by quality compliance managers in the biotech industry to integrate FDA
quality compliance requirements into their products’ quality metrics. To attain this goal, I
selected a qualitative method and a multiple case study design.
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Research Method
I selected qualitative methodology for this study to explore the strategies used by
quality compliance managers to integrate FDA quality compliance requirement into their
products’ quality metrics. Researchers use the qualitative method to explore and analyze
perceptions and experiences of people who are involved in an activity or process (Hoeber
& Shaw, 2017). Through the effective use of qualitative methodology, researchers gain a
deeper understanding of why study participants make decisions (Rosenthal, 2016). In the
current study, the qualitative method was appropriate to provide a deeper insight into the
strategies used by quality compliance managers in the biotech industry to integrate FDA
quality compliance requirements into their products’ quality metrics.
By contrast, researchers use quantitative method to analyze and examine
relationships among variables using numerical data and hypotheses (Walsh, 2015). A
quantitative method was not ideal for the current study because I did not test a
hypothesis. Bernard (2013) argued that the researcher must carefully consider other
alternative research methods before selecting an appropriate research method. Ritchie et
al., (2016) stated that quantitative or mixed-methods approaches are not appropriate for
studies that probe the study participants’ underlying decision-making process. In the
current study, I intended to probe the participants’ underlying decision-making process:
therefore, the quantitative or mixed-methods approach would have been inappropriate.
Research Design
The primary function of a research design is to ensure that the evidence gathered
by the researcher can be used to effectively answer the research questions. Qualitative
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researchers use the research design to ensure research reliability and validity (Noble &
Smith, 2015). I selected a case study design for this study. Researchers use the case study
design to gain a deeper understanding of the study subject (Fusch & Ness, 2015). Yin
(2017) argued that researchers use the case study design to preserve the universal and
evocative characteristics of a real-life event. I selected a case study design for this study
because I intended to present the realities described by participants.
Other qualitative designs did not support the explorative nature of this study. The
phenomenological design would have allowed the collection of interview data for this
study, but the phenomenological design would not have allowed the collection of
publicly available data from multiple sources; therefore, the phenomenological design
was not appropriate for this study. Researchers use the ethnographic design when
examining beliefs and behaviors of culture-sharing groups (Marshall & Rossman, 2016).
I did not select the ethnographic design for this study because I did not examine cultures
and behaviors. The ethnographic design was inappropriate to explore the strategies used
by quality compliance managers to integrate FDA quality compliance requirements into
their products’ quality metrics.
Population and Sampling
Sampling addresses the number of participants, the number of contacts with each
participant, and the length of time spent with each participant (Marshall & Rossman,
2016). Purposeful sampling is used to identify and select cases related to the research
phenomenon in a qualitative study (Fusch & Ness, 2017). The sampling of research
participants involves affirmation that each participant meets the selection criteria
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(Marshall & Rossman, 2016). Purposive sampling is suitable in studies in which the
researcher seeks participants with the best knowledge concerning the research topic (Yin,
2017). I used purposeful sampling in this study in the selection and engagement of the
study participants.
I used Zoom interviews to collect data. Interviewees were the primary source of
data for this study. As Yin (2017) noted, well-informed participants with the appropriate
knowledge can add important and needed data to the study. Unlike in a quantitative study
where researchers choose random sampling to obtain reliable inferential results,
qualitative researchers use a nonprobabilistic approach to choose the sample. In the
current study, I used purposeful nonrandom sampling to choose five study participants.
Robinson (2014) referred to purposive sampling strategies as a nonrandom selection of
participants as part of a final group based on the uniqueness of the knowledge that they
possess. I used purposive sampling to select participants with proven experience and
knowledge of FDA quality compliance requirements.
The researcher may not set an exact number of research participants; however, an
initial range is necessary to establish effective research planning (Robinson, 2014). For
instance, Marshall et al. (2013) interviewed 83 participants and concluded that the
minimum number of cases in a multiple case study was two while the median was five.
Further, Marshall et al. noted that the minimum number of interviews was 10 while the
median was 39. In the current study, I interviewed five participants with knowledge and
experience in addressing FDA quality compliance requirements. I collected data from
five experienced quality compliance managers until data saturation was reached. Data
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saturation occurs when exploring a problem under study offers no new or additional
themes (Fusch & Ness, 2017). This selected population was enough to provide a robust
understanding of the strategies used by biotech quality compliance managers to integrate
and apply FDA quality compliance requirements into their products’ quality metrics.
The specific population consisted of five quality compliance managers from two
biotech companies in the West region of the United States who had experience applying
and integrating FDA quality compliance requirements in their products’ quality metrics. I
conducted the interviews in a quiet and conducive environment. As Cahyadi and
Prananto (2015) opined, an interview should take place in a quiet location free from
distractions with little or no noise. Further, Cahyadi and Prananto suggested that a place
suitable for audio recording is ideal for a study interview. Also, the researcher should ask
the participants to choose the location and time of the interviews (Yin, 2017). Yin further
noted that a good rapport before the interview is crucial to a successful interview because
good rapport reduces the participant’s discomfort, which can yield better answers to the
interview questions. Based on these recommendations, I asked the participants to select
an interview date, time, and location that was most suitable for them. I developed good
rapport by asking about their day and other unrelated questions before the interview
questions.
Ethical Research
Walden University’s IRB procedures were used as a guide for this study. Walden
University’s IRB requires that each study participant receives an informed consent form
that identifies the (a) purpose of the study, (b) researcher’s responsibilities, (c) procedures
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for ensuring confidentiality, and (d) participant’s role (Walden University, 2015).
Obtaining participants’ informed consent is a core component of ethical research
(Gaikwad, 2017). I obtained participants’ consent to participate in this study by sending
an informed consent form and a consent procedure letter via email to study participants.
The procedure letter outlined the background and procedural information about the study.
The procedure agreement included a clear and concise description of the study topic,
sample interview questions, and participants’ expectations regarding compensation or any
other form of reward for participating. The consent form stated that the benefit of the
study was to the public, and for participating participants would get a copy of the
completed study if they chose to.
After I determined that participants had met the selection criteria, the research
participants received an invitation to participate email from me. Upon returning the email
communicating an interest to participate in the study, participants received another email
with the consent form attached. The informed consent form contained information about
the strict ethical compliance of the study, such as participants’ ability to withdraw their
consent at any time during their participation. Participants were free to withdraw their
consent to participate by sending an email to me stating that they did not want to
participate any longer. Participants did not need to provide reasons why they were
withdrawing their consent to participate. The consent form, which the participants were
required to return before participating, ensured participants that their privacy and the
privacy of their organization would be a priority. This study was conducted using
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Walden’s ethical research procedures and the standard guidelines for qualitative research
involving human subjects.
Strict adherence to ethical guidelines is an important aspect of qualitative research
involving human subjects (Robinson, 2014). The research in this study is conducted in
accordance with the recommendations in the Belmont report of 1979 which is the
acceptable minimum standard for conducting research involving human research
participants (U.S Department of Health and Human Services, 1979). I followed the
recommendations contained in the Belmont report to ensure the adequate protection of
this study participants. This research was conducted after approval and an approval
number was received from Walden University’s IRB. The approval number from the IRB
for this study is 09-22-20-0660779. The study reports are protected using generic names.
I did not use the actual names and location of any research participants and their
organization. The research study data are stored on a password protected computer with
codes and generic names. I stored all study related documents in a password protected
thumb drive. I will store the password protected thumb drive in a locked safe for five
years.
Data Collection Instruments
The researcher assumes the primary role of data collection and as such, the
researcher is the primary data collection instrument in a case study (Gaikwad, 2017; Yin,
2017). The use of semistructured interviews and probes contribute to the validity and
reliability of a qualitative study (Morse, 2016; Yin, 2017). In this qualitative case study, I
collected data from review of public documents, news releases, website information, and
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conducted face-to-face semistructured interviews. I interviewed individuals in
biopharmaceutical quality compliance leadership positions in three biotech companies in
West region of the United States. The study participants were responsible for the design,
management and administration of supply chain management strategies used in their
respective organizations to attain and apply FDA quality compliance requirements into
their products’ quality metrics. Marshall and Rossman (2016) opined that data
triangulation of multiple sources is used to give credibility to a research outcome. Yin
further noted that, case study researchers could use effective data triangulation by
collecting pertinent information from multiple sources to corroborate the same
phenomenon and ensure the overall study quality.
Data Collection Technique
I collected data via semistructured interviews, and the review of strategies used by
quality compliance managers to integrate FDA product quality compliance requirements
into their product quality metrics. In semistructured interviews, the researcher uses a set
of open-ended questions combined with probes to explore participant responses
(Rosenthal, 2016). Qualitative researchers should follow an interview protocol to conduct
all interviews in a consistent manner and collect data from more than one source to
achieve triangulation (Morse, 2016). In this study, I followed a semistructured interview
protocol that would use open-ended questions combined with probes to explore the
strategies used by quality compliance managers in the biotech industry to attain full FDA
quality compliance requirements. I used interview protocols that contained steps for
conducting a research interview, discussion of member checking, and explanation of
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strategies. By following this semistructured interview and document review protocols, I
was able to explore the strategies used by quality compliance managers in the biotech
industry to integrate FDA quality compliance requirements into their products’ quality
metrics.
There are some disadvantages as well as advantages to collecting case study data
in a semi structured interviews and in reviewing company data and documents. One of
the advantages of collecting data through a semistructured interview is that the openended questions may prompt the study participants to answer questions as well as provide
additional perspectives gained through experience (Rosenthal, 2017). Additionally,
probing questions may be used to clarify information as well as create and explore a
recurring theme (Gaikwad, 2017). The use of probing questions and review of company’s
data and documents may contribute to the research reliability and validity (Fusch & Ness,
2016). The advantage of these open-ended research questions listed in Section 1 and the
review of relevant company documents will enable me to explore the strategies used by
quality compliance managers in the biotech industry to attain full FDA quality
compliance requirements.
One of the disadvantages of collecting data through a semistructured interview
and the review of company data and documents is the amount of time involved in
completing the process and analyzing the documents. Semistructured interviews and
document reviews are time consuming and may create project creep in the research
process (Rosenthal, 2017). As Gaikwad (2017) noted, the researcher should include an
adequate time to complete these required steps: (a) scheduling and conducting interviews,
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(b) document reviews, (c) transcription, and (d) member checking. To mitigate this
disadvantage, I asked study participants to reserve an hour to review a summary of the
interview for accuracy and to provide any additional information if needed. Therefore,
time constraint would not impede the success of exploring the strategies used by quality
compliance managers in the biotech industry to integrate FDA product quality
compliance requirements into their product quality metrics.
Data Organization Technique
I organized the research data by creating and maintaining an electronic data logs
on a password-protected computer. The researcher should categorize collected data and
store the data in a safe and secure format with easy to retrieve capability (Baskarada,
2016). The entries in the log that I created included data information such as (a) the data
type, (b) data identifier, (c) date of collection, (d) place of collection, and (e)
corresponding research notes identifier. I recorded notes during the interviews. Microsoft
Excel and NVivo are the standard tools used by qualitative researchers for data collection
and organization, data analysis and data reporting (Bree & Gallagher, 2016; Robins &
Eisen, 2017). I collected data such as the consent form, audio recording, or transcription.
I used a secured easy to retrieve Microsoft Excel and Microsoft Word interface to
organize and secure collected research data.
To keep collected data secure and organized, I created and labelled folders for
each research participant. I used alphanumeric codes for each folder labels. I labelled
audio recordings, consent forms and interview transcriptions with alphanumeric
participants’ code (e.g., P3 Consent Form) and stored it in the participant’s folder. To
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effectively analyze collected data such as interview transcriptions, I copied the
transcribed interview data into an excel spreadsheet with appropriate headings (e.g.,
document code, participant code, question number, and responses).
I stored electronic data gathered for this study in a password protected laptop. I
stored physical data in a locked safe. I stored all electronic data in a password protected
thumb drive and delete all electronic data from my laptop after the study is completed. I
will store the thumb drive and the physical data in a safe for 5 years. Afterwards, I will
delete the electronic data from the thumb drive, and I will shred the physical data.
Data Analysis
In qualitative research studies, researchers analyze and gather data during
interviews to identify emerging themes (St. Pierre & Jackson, 2017). In this study, I
identified emerging themes through methodological data triangulation by (a) interviewed
qualified and experienced quality compliance managers with more than 15 years of
quality management experience within the biotech industry, (b) interviewed FDA
regulatory compliance officers, and (c) reviewed quality compliance documents used to
attain FDA quality compliance requirements by the biotech industry. The use of multiple
data sources provides researchers with a comprehensive knowledge of a researched
phenomenon while applying methodological data triangulation (Carter, Bryant-Lukosius,
DiCenso, Blythe, & Neville, 2016; Joslin & Muller, 2017).
Qualitative researchers analyze data to discover themes that can answer their
research question (Yin, 2017). In this study, the objective of the data analysis was to
discover the strategies used by quality compliance managers in the biotech industry to
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attain FDA quality compliance requirements. Defining the process and tools used for data
analysis is an important step in the research planning phase in a case study (Rosenthal,
2017). As Hoeber and Shaw (2017) noted, methodological triangulation requires the use
of more than one method to gather data. The documents review will include published
FDA regulatory documents, organizations compliance documents and the responses to
developed open-ended interview questions and other company documents such as FDA
citation letters. Themes discovered during these data analysis provided the framework for
addressing this study research question. I used more than one data sources such as coding
and thematic data analysis.
Yin (2017) recommended five stages of data analysis: (a) compiling, (b)
disassembling, (c) reassembling, (d) interpreting, and (e) drawing conclusions. Yin
further noted that compiling data refers to the process of collecting and organizing data.
Disassembling and reassembling include separating data and organizing data into groups
and identifying data patterns and or themes. Interpreting data involves associating the
emerging themes with existing research and the conceptual framework (Yin, 2017). I
used Microsoft Word and Excel functions to gather data, disassemble, and reassemble
interview data into meaningful themes. According to Ose (2016), the standard Microsoft
Office program comes equipped with functionality ideal for organizing and coding
qualitative research data. Whereas some researchers disregard Microsoft Excel as a viable
means of organizing and coding qualitative research data (De Felice & Janesick, 2016),
Moylan et al. (2016) opined Microsoft Office programs are the most viable, cheaper
alternative to expensive data analysis programs for qualitative research.
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Per Yin’s (2017) data analysis methodology, the next step was to interpret the
themes and their meaning. I compiled collected data from interviews and company
documents and identified emerging themes through the interactive process of disassembly
and reassembly. As I defined emerging themes, I related the themes to supply chain
management strategies for attaining FDA product quality compliance information in the
literature review, Deming’s quality management theory, and newly published FDA rules
and other related scholarly articles. Based on these data triangulation and interpretation, I
drew and reported my research conclusions.
Reliability and Validity
Research reliability and validity refers to the research quality and result of the
research outcome (Gaikwad, 2017). Research reliability and validity are related with the
research dependability, transferability, and credibility (Morse, 2015). Fusch and Ness
(2015) noted that, when conducting a qualitative research study, the researcher should
adopt research techniques that contribute to the research reliability and validity.
Qualitative researchers use four model criteria to ensure research data trustworthiness.
The model’s four aspects are: (a) credibility, (b) dependability, (c) confirmability, and (d)
transferability (Cope, 2015; Morse 2015).
Reliability
Research reliability in a qualitative research study is analogous to the research’s
dependability (Gaikwad, 2017). Dependability refers to the reliability of the research data
over time and in a different context (Cope, 2015; Morse, 2015). Qualitative researchers
use different methods and strategies to attain dependability. Qualitative researchers use
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member checking and case study protocols to solidify research findings (Cope, 2015).
Fusch and Ness (2015) noted that, interview protocols and member checking increase the
levels of data reliability obtained from research participants. Researchers engage study
participants in the member checking process through semistructured interviews by which
participants review data provided by the member for accuracy and authenticity in
comparison to similar data from the same or other sources (Cope, 2015). Researchers link
reliability and confirmability through similar means (Morse, 2015).
Confirmability refers to the objectivity of the research and the absence of personal
bias in the study (Cope, 2015). According to Morse (2015), the study findings must be
firmly rooted in participants’ data without any part of the data invented by the researcher
or influenced by personal bias. In this study, confirmability will occur through member
checking, data interpretation and participants’ interview summary reviews. In addition to
member checking of data interpretation and transcript reviews, I will use reflective
journals to create an audit trail of findings. Reflective journals represent a remarkable
tool used by qualitative researchers to document research observations, analytical
findings, and emerging themes (Young & MacPhail, 2016).
In this study, to ensure reliability, I utilized interview protocols, member
checking, and reflective journaling. I conducted each interview using the same interview
protocol (Appendix D) to ensure the same data collection method throughout the research
data collection process. I used the same interview questions and the same interview
protocols for all research participants. After each interview, I sent the same interview
synthesis and interview summary to all the participants to validate my interpretation of
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their given interviews and data. As Harvey (2016) noted, member checking gives the
interviewee the opportunity to confirm the accuracy of the researcher’s depiction of their
experiences. I used a reflective journal to document all my observations throughout the
interviews and data review in order to gain insights on emerging themes.
Validity
Qualitative research quality is dependent on the qualitative researcher’s focus on
key means of study validity (Marshall & Rossman, 2016). Accordingly, qualitative
researchers ensure the validity of their research using credible procedures (Denzin &
Lincoln, 2015; Marshall & Rossman, 2016). Qualitative researchers assess research
trustworthiness by adopting the model by Lincoln and Guba which considers: (a)
credibility, (b), dependability, (c) confirmability, and transferability (Cope, 2015; Morse,
2015). Qualitative researchers use data triangulation and member checking to gain
research internal validity (Berger, 2016). Credibility refers to a qualitative research
internal validity whereas transferability refers to external validity (Morse, 2015).
Transferability refers to the extent to which other researchers can replicate the
study in a different context and would get the same results (Elo et al., 2016).
Transferability describes the participants and data selection and gathering processes in a
manner that, other researchers can replicate the processes in a different context and will
get the same result (Morse, 2015). Confirmability is the degree of objectivity of the
research and the absence of any personal bias on the part of the research participants
(Cope, 2015). Research credibility refers to the truth, testability, and authenticity of the
research data in a qualitative case study whereas dependability refers to the ability of
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other scholars to rely on the research outcome (Morse, 2015). Data saturation ensures
dependability and research validity (Cope, 2015).
Data saturation occurs at the point at which no further new information or theme
is emerging (Fursh & Ness, 2017; Houghton et al., 2015). Researchers reach data
saturation through data triangulation and member checking as well as participants’
transcript reviews (Houghton et al., 2015) Abma and Stake (2016) identified member
checking as a reliable mean to reach data saturation.
In this study, I attained data transferability by ensuring data validity and
authenticity through member checking and multiple source reviews of collected data. I
compared published FDA regulatory documents with data collected from participants to
ensure currency and reusability by future scholars. I provided detailed descriptions of the
study context so that future readers can determine for themselves the level of the
applicability of the study in their future selected context. I ensured credibility through
member checking, participants’ transcript reviews and data triangulation. I interviewed
only participants with 15 to 20 years of experiences attaining FDA quality compliance
requirements in a nationally recognized biotechnology firm. I made participants review
my synthetization of their documents and interview summary for accuracy and true
depiction of their highlighted strategies use to integrate FDA quality compliance
regulatory requirements into their product quality metrics. I addressed confirmability by
member checking, participants’ interview transcript reviews and data triangulation to
ensure personal bias do not form part of the data synthesizing.
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Data saturation is an important aspect of the qualitative research study (Fursch &
Ness, 2017). According to Abma and Stake (2016), the researcher reaches data saturation
when no new information or theme is emerging. I attained data saturation by a
methodological data triangulation through giving interviewees the opportunity to provide
additional and new information. This study data saturation was reached when no new
information or theme is emerging from additional information and documents.
Transition and Summary
In section 1, the chosen research method and design for this study is the
qualitative case study. The research population is five biotech quality compliance
managers from biotech firms in the West region of the U.S. The participants have
designed and implemented quality compliance strategies to attain FDA product quality
compliance. The conceptual framework governing this research study is Deming’s
strategic models for developing and implementing quality (Deming, 1986). The statement
of the problem and study purpose is consistent with how quality compliance managers
perceive the challenges faced when responding to FDA quality regulatory compliance
requirements.
In section 2, I described: (a) the role of the researcher, (b) the population and
sampling methods, (c) data collection and analysis techniques, (d) a description of the
research participants, and (e) explanation of the ethical research process. Further, section
2 contains a description of the research reliability and validity. Section 3 contains a
detailed presentation of the research findings. In this section I present recommendations
for actions as well as suggestions for future research study.
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Section 3: Application to Professional Practice and Implications for Change
Introduction
This section includes the presentation of findings gathered from semistructured
interviews with product quality compliance managers in the U.S. biotechnology industry
with more than 15 years of FDA quality compliance implementation experiences within
their selected organizations. This section also contains the application to professional
practice, implications for social change, and recommendations for action. The section
concludes with recommendations for further research, a reflection on my experience, and
a summary of the study.
Presentation of the Findings
The purpose of this qualitative multiple case study is to explore the strategies used
by quality compliance managers in the biotech industry to integrate FDA product quality
compliance requirements into their products’ quality metrics. Deming’s (1986)
management theory is the conceptual framework for this study. Using purposeful
sampling and semistructured interviews, I interviewed five quality compliance managers
with 15 or more years of experience implementing FDA product quality compliance
requirements within the biotech industry in the West region of the U.S. The interviews
were conducted via Zoom and were recorded, transcribed, and coded by using red text to
identify themes. NVivo 12 software was used to establish significance, codes, and
phrases among data sources. The analysis of the interview transcripts resulted in the
identification of 42 codes and 300 meaningful quotes and phrases that supported the
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identification of emerging themes. The emerging themes confirmed the study’s
underlying conceptual framework.
Three themes emerged from my analysis of the aggregation of the codes, phrases,
and terms that summarized the strategies used by quality compliance managers to attain
FDA product quality compliance requirements (see Table 1). The three themes were (a)
product quality outcomes, (b) policies and procedures, and (c) collaborative partnerships.
The three themes supported the conceptual framework of Deming (1986) and aligned
with the research topic of the strategies used by quality compliance managers to attain
FDA product quality compliance. The alignment of the emerging themes is seen in
current peer-reviewed studies such as Anwar et al. (2016) and Mirza and Ahsan (2020)
who noted that defining quality outcomes and determining required collaborative
partnerships are key to product quality management.
Table 1
Cluster Related to the Three Emerging Themes
Participant

P1
P2
P3
P4
P5
Total

Partnership

38
60
21
27
33
179

Product quality
outcome
84
123
56
37
55
155

Policies and
procedures
collaborative
6
24
9
13
19
71

Emergent Theme 1: Product Quality Outcomes
The first theme of the study indicated the strategic processes used by quality
compliance professionals to define product quality outcomes that are used in the industry

68
to attain FDA product quality compliance. The participants identified the efficacy of
clear, simple, and easy-to-follow product quality outcomes as a strategic requirement for
attaining FDA product quality compliance. This theme was highlighted by all participants
and was recorded in my notes. In creating a strategy for attaining expected quality
outcomes, participants identified three strategic methods, practices, and rules adopted
across the industry. Table 2 depicts the response frequencies for highly summarized
strategies in Emerging Theme 1.
Table 2
Theme 1: Product Quality Outcomes
Theme
Product quality

Number of
participants
5

Number of
documents
3

Number of
references
179

All five participants identified a clearly defined product quality outcome as one of
the primary requirements for creating a product outcome that meets an FDA product
quality requirement. P1 noted that “the organization must design a clearly defined
product quality outcome that all employees involved in the quality process should
understand and adhere to.” Further, in describing product quality outcome as a key
theme, three subthemes emerged, as shown in Table 3.
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Table 3
Subthemes Related to Emerging Theme 1 of Product Quality Outcomes
Subtheme
Training
Buy-in
Verifications

Participant
P3, P4, P5
P1, P2, P3, P4,
P5, P6
P1, P2, P3, P4,
P5, P6

Number of
documents
4
5

Number of
references
25
60

5
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Employee training is required to attain intended product quality outcomes. As a
corollary, Participant 4 stated that “employee training and commitment is the first port of
call in the pursuit of product quality compliance requirements.” Participant 2 stated that
it should be emphasized that, only the employees who display understanding and
mastery of the product quality outcome who should be allowed to be a part of the
quality compliance team to develop a product that complies with FDA quality
regulatory requirements.
Participants 3, 4, and 5 agreed. Participant 4 went further and stated that “regular quality
compliance training and verification of understanding is required to earn expected
product quality outcomes.” Participant 3 also noted that “in any organization where
employees involved in product quality compliance don’t understand the product quality
compliance requirements, FDA quality compliance citation increases in that
organization.” Anwar et al. (2016) opined that consistent verification of employee
competencies is required to maintain product quality outcomes.
Employee and management buy-in emerged as a subtheme of Theme 1. Employee
trainings and total buy-in are fundamental requirements in defining product quality
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outcomes (Mirza & Ahsan, 2020). Participant 5 stated that “employees must sign some
form of documents stating that they understood the product quality requirement and that
they support the processes.” Jagsi et al. (2014) argued that training alone is not enough
practice to earn total quality management credits within the organization. Jagsi et al.
noted that confirmed employee buy-in is required at every level of the organizational
quality compliance campaign. Participant 5 noted that buy-in gives the employees the
opportunity to state their concerns should there be any. Discussing the effectiveness of
employee buy-in, Participant 5 further stated that “it’s a continuous learning and
relearning process.” Deming (1986) argued that quality management within an
organization requires consistent management commitment to employee buy-in.
All participants further opined that, to create a quality product outcome,
organizations should implement a step-by-step quality outcome measurement and
verification process using confirmable technological systems. Participant 5 noted that,
whereas employee training is required, management are expected to put in place “a
system to verify full and total quality management systems requirement and adherence by
employee.” Bajaj et al., (2019) noted that providing compliance and adherence incentives
such as training and performance feedback could help employees follow a step-by-step
compliance verification requirement within the product quality compliance department.
According to Rijsbergen et al. (2016), though management trust employees to comply,
the need to track, verify, and improve product quality compliance should be routine
within the quality management department. Participant 5 noted that “the compliance
documentation and verification requirement is a key requirement.” All study participants
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noted that the creation of a well-defined product quality outcome is made possible by
engaging in step-by-step recorded employee participation and adherence to the assigned
product quality.
Product quality outcomes should be defined and clearly outlined. Deming (1986)
noted that quality management theory recommends that quality outcomes are clearly
defined as part of the product management processes in an organization. Also,
Rijsbergent et al. (2016) opined that defining the quality outcome from the onset is an
established product quality management technique. All current participants agreed.
Participant 3 stated that “understanding of the quality outcomes is the first place to start,
and management must ensure all quality management participants understand the product
quality outcomes.” Deming (1986) argued that organizations must define quality
outcomes and help employees understand the outcomes by providing the guidance
needed to attain outlined outcomes.
Emergent Theme 2: Policies and Procedures
The second theme that emerged was the importance of organizational product
quality policies and procedures. All five participants identified organizational policies
and procedures as an integral part of product quality compliance outcomes. Table 4
reflects Theme 2 that emerged from the analysis of the five participant transcripts and
review of available practice documents.
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Table 4
Theme 2: Policies and Procedures
Theme
Policies and
procedures

Number of
participants
5

Number of
documents
12

Number of
references
155

All participants noted that organizational policies set the tone for product quality
compliance. Participants 3 and 4 noted that, beyond organizationally stated policies for
compliance, defined compliance procedures are vital. Participant 1 stated that “the FDA
has clearly defined compliance policies, but most of these policies are recommendations.
The individual organization is expected to design their own internal policies to reflect and
follow the FDA guidance and compliance policies.” Participant 3 further noted that
corporate policies and procedures form the basis of quality compliance: “every
organization must signal a culture of compliance by establishing a clear quality
compliance policy within the organization.” Martyn et al. (2016) stated that policies and
procures are organizations’ strategies that create a culture within an organization.
Organizations design and implement corporate strategies to implement intended
corporate outcomes (Pinto & Winch, 2016). The implementation of corporate policies
and procedures such as quality compliance procedures within an organization needs to be
clearly defined (Alqahtani, 2016). In describing policies and procedures as a recurring
theme, several subthemes emerged. Table 5 highlights the different subthemes mentioned
by study participants.
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Table 5
Subthemes Related to Emerging Theme 2 of Policies and Procedures
Subtheme
Compliance
tone
Accountability
Policy clarity
Strict
adherence

Participant

Number of
documents

P1, P5

4

Number of
references
10

P1, P2, P3, P4,
P5
P1, P2, P3, P4,
P5
P5, P4, P3

5

30

2

55

1

5

The core aspect of this theme aligned with the conceptual framework of this
study, Deming’s (1986) quality management theory. Deming argued that quality
management in a production process accentuates an organization’s competitiveness and
sustainability, and organizations should make such quality notions part of their overall
policies and procedures. In practice, the strategic use of policies and procedures to attain
product quality and overall organizational effectiveness is an indispensable aspect of
product quality implementation (Alqahtani, 2016).
Emergent Theme 3: Collaborative Partnerships
The third theme that emerged from this study was collaborative partnership. All
participants identified collaborative partnership within and outside the organization as a
key requirement for product quality compliance (see Table 6). Participant 1 noted that
“organizations, in order to attain FDA product quality compliance requirements, must
look beyond their own organization and look into processes by other partners.”
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Table 6
Theme 3: Collaborative Partnerships
Theme
Collaborative
partnerships

Number of
participants
5

Number of
documents
9

Number of
references
71

Participant 2 argued that the requirement to comply with regulatory quality
compliance starts with management and frontline employees. Participant 2 argued that
“management must understand frontline needs and requirement and put on a
collaborative hat to fully attain FDA product quality requirement.” Further, Participant 5
noted that “companies who want to attain compliance and avoid huge violation penalties
must partner with external agents and experts to provide compliance training.” Participant
1 noted that “every department within the organization must collaborate on the need to
attain product quality compliance to attain full FDA product quality compliance.”
Further, Participant 4 stated that “collaborative partnership is required throughout the
product life cycle.” All participants agreed that FDA product quality compliance requires
internal and external collaborative partnerships. Participant 3 noted that “quality
compliance is an all-hands-on-deck requirement, from product conception to product
end-users.” Hernández‐Carrión et al. (2017) noted that organizations thrive when they
have a successful partnership within and outside their organizations. In identifying
Emergent Theme 3, I observed several subthemes (see Table 7).
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Table 7
Subthemes Related to Emerging Theme 3 of Collaborative Partnerships
Subtheme
Internal
collaboration
External
partnerships
Collaboration

Participants

Number of
documents

P1, P5

4

Number of
references
10

P1, P2, P3, P4,
P5
P1, P2, P3, P4,
P5

5

30

2

55

The improve-every-process aspect of Deming’s (1986) quality management
theory aligned with the collaborative partnerships theme of the current study. According
to Deming, organizations must partner and collaborate with every process of the product
or services for a single goal of product quality improvement. Participant 1 noted that
“quality compliance managers must partner with external participants to attain product
quality improvement.” Also, Fawcett et al., (2016) suggested that better product
improvement success rate occurs within the organization and desired quality outcome is
attained through collaborative participation across all spectrums. Deming’s product
quality management theory was an appropriate framework for monitoring and engaging
multiple participants within a product quality outcome effort. When engaging employees
to attain product quality within an organization, leadership can use Deming’s quality
management theory to assist in this process.
Applications to Professional Practice
The result of this study provided strategies that quality compliance managers in
the biotech industry can apply to obtain FDA product compliance requirements.
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Compliance managers in the biotech industry are responsible for the implementation of
FDA product quality compliance requirements. Still, many organizations within the
biotech industry face product recalls for lack of quality compliance and are often fined
for lack of compliance (Smith & Rupp, 2016). Current research indicates that many
compliance managers are unable to integrate FDA product quality requirements into their
quality metrics (Chellener, 2020).
The theme identified in this study are product quality outcomes, policies and
procedures and collaborative partnerships. Each of these themes are product quality
compliance strategies that different quality compliance managers throughout the Western
region of the United State have identified as strategies used by experienced compliance
managers to attain full FDA product quality compliance requirements.
Quality compliance managers can attain FDA product quality compliance through
several ways. The themes in this study are significant and supports the professional
practices in the region. The use of strategies such as Demings quality improvement
strategies can help quality compliance managers attain FDA quality product requirements
(Deng et al., 2019). Further, Harold et al. (2016) noted that, quality management
strategies can be used to attain full quality improvement within the biotech industry.
Implications for Social Change
According to Haugh and Talwar (2016), positive social change is grounded in the
elimination of restrictions that prevent or hinders the progress of an organization and, or
community. Implications for social change for the biotech industry includes jobs and
availability of much needed drugs for societies. Growth in the biotech industry would
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improve the overall welfare and living conditions of the public. Also, the education and
communication of new quality improvement strategies within the organization could
improve employee morals. According to Oskooee (2017), positive change initiatives can
increase employee commitment and reduce resistance. Therefore, the communication and
implementation of quality compliance strategies within the industry can have positive
effect on the success and growth of the industry resulting from a motivated workforce.
Recommendations for Action
Despite numerous quality compliance and good manufacturing publications by
the FDA, many organizations within the biotech industry have failed to attain required
FDA product quality compliance requirements. Consequently, more than 70% of
businesses fail to attain the required quality compliance (Cândido & Santos, 2015). The
findings of this study may assist current and future business leaders in managing the
challenges associated with effectively implementing required product quality compliance
within the biotech industry. Based on the research findings, from this study, the results
are significant to organizational leaders and quality compliance managers because they
may benefit from the participants’ experience and the strategies revealed for the
successful implementation of the strategies used to attain FDA product quality
compliance requirements.
Additionally, other manufacturing organizations, besides those in the biotech
industry could also benefit from implementing the quality implementation strategies
enunciated in this study. Service organizations in the public and private sectors, profit
and non-profit organizations may benefit from the findings in this study. The findings
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from this study may be published as a resource to business leaders through journal
articles and professional literature. Also, the findings of this study would be shared at
conferences, seminars and in business courses that I teach.
Recommendations for Further Research
The purpose of this study was to help contribute to the gap of the lack of or
ineffective strategies used by quality compliance managers in the biotech industry to
attain FDA product quality compliance requirements. I recommend further research on
this subject. The limitations of the study were the sample size of three biotech
organizations in the Southern region of the United States not being a representation of all
the biotech organizations in the United States. Although data saturation was reached in
this study, extensive research with a broader group of participants is recommended. The
other limitation of this study was that participants might not have provided honest
answers to the interview questions that may have effectively represent the strategies used
within their organization to attain full FDA product quality compliance requirements.
Reflections
The Doctor of Business Administration (DBA) program at Walden University
was challenging, yet astonishingly rewarding. I did not anticipate the amount of time and
energy required to complete the doctoral study, and as a result, I experienced a few
setbacks. However, the knowledge obtained throughout this process was fulfilling. I took
required actions to identify and limit my personal biases within the scope of this study. I
followed an established interview protocol when conducting interviews with participants
to mitigate bias. I also conducted member checking by having the participants review a
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summary of my interpretations of the interview responses to ensure research validity. I
am also very glad that, in the process of this study, I became familiar with FDA quality
compliance regime and the strategies used by the biotech industry to attain product
quality compliance.
Conclusion
To attain FDA product quality compliance requirements, organizations must
create and adopt effective quality compliance strategies throughout all organizational
product manufacturing processes (Mirza & Ahsan, 2020). Although organizations within
the biotech industry thrive to attain product quality compliance, many of these
organizations continuously gets cited for failure to adopt and implement product quality
compliance requirements. Accordingly, Challener (2020) noted that, a culture of
compliance is required within the organizations’ manufacturing processes. In this study, I
used open-ended, semistructured questions to interview five quality compliance managers
in the Southern region of the United States. Data saturation occurred once information
became repetitive. From these interviews, three major themes emerged from the collected
data: product quality outcomes, policies and procedures, and collaborative partnerships.
The themes which emerged from this study may form the basis upon which effective
product quality regimes could be attained by product manufacturers in the biotech
industry. Product quality compliance professionals may apply the findings from this
study to attain full FDA product quality requirements.
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Appendix: Case Study Interview Protocol Checklist
Pre-Interview
Interview date:

Interview time:

Interview location:

Interview duration estimate:

Participant pseudonym:

Participant code:

Interview documentation and materials
Receipt of Informed Consent (Yes or

Eligibility criteria met (Yes or No):

Receipt of Permission to Record and

Test Primary and back-up recording

No):

Transcribe (Yes or No):

device
(Yes or No):

Conduct of interview
Introductions (Yes or No):

Overview of research topic (Yes or
No):

Discuss purpose

Questions from participant (Yes or
No):

Discuss risk

Questions from participant (Yes or
No):

99
Discuss confidentiality

Questions from participant (Yes or
No):

Discuss right to withdraw

Questions from participant (Yes or
No):

Discuss benefits

Questions from participant (Yes or
No):

Discuss data security

Questions from participant (Yes or
No):

Interview
My observations and actions:

a)

What leadership strategies do

you use to embed a culture of quality and
compliance within your company
a. Body language
b. Non-verbal cues
c. Paraphrasing
d. Probing questions

b) How does your management team

e. Follow-questions

formulate and adopt product quality
compliance techniques?
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c) How does your organization
integrate quality compliance strategies into
your internal and, or external quality
compliance metric systems?

d)

What total quality

management processes and tool does your
organization use to implement your quality
management strategies?

e)

How does your organization

identify the key opportunities for quality
improvement within your quality and
compliance processes to assure FDA quality
compliance requirements are met?

f)
What, if any, supply chain management
technologies do your organization use to address key barriers to
101your product
integrating FDA product quality requirements into
quality metrics?

g) What other information can you provide about the
strategies used by your organization to apply and integrate
FDA’s quality compliance requirements into your products’
quality metrics?

Post-interview follow-up
Thank participant for contribution

Actual interview duration:

Discuss next steps:

Questions from participant (Yes or
No):

a. Completion of transcript
b. Concept of member checking
c. Set up a date for member checking follow-up
d. Notification of findings
e. Duration of data security

Questions from participant (Yes or
No):
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Member checking follow-up
Follow-up date:

Provide copy of synthesis for each
question

Introduce member checking process

Questions from participant (Yes or
No):

My observations and actions:

a) Synthesis of 1st question

• Additional probing questions

b) Synthesis of 2nd question

• Affirm synthesis for each question

c) Synthesis of 3rd question

• Ask for further interpretation or additional information

d) Synthesis of 4th question

• Ask what was missed in the initial interview

e) Synthesis of 5th question
f)

Synthesis of 6th question

